Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688336's Return-on-Tangible-Equity is ranked better than 94.92% of 1200
companies
in the Biotechnology industry
Industry Median: -42.305
vs SHSE:688336: 46.83
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sunshine Guojian Pharmaceutical (Shanghai) Co Return-on-Tangible-Equity Related Terms
Sunshine Guojian Pharmaceutical (Shanghai) Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co Return-on-Tangible-Equity Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
SHSE:688336 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co Return-on-Tangible-Equity vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.93% mean?
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Return-on-Tangible-Equity of 8.93% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. This is 19% below median its historical median of 11.00. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #61 out of 1200 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Return-on-Tangible-Equity too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Return-on-Tangible-Equity of 8.93% is 19% below median its 10-year median of 11.00. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #61 out of 1200 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #61 out of 1200 companies for Return-on-Tangible-Equity. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Return-on-Tangible-Equity is 8.93%, which is 19% below median its own 10-year median of 11.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Possible Value Trap. The stock's GF Value™ is ¥67.37, compared to a current price of ¥42.70 — trading 36.6% below its estimated fair value. The current Return-on-Tangible-Equity is 8.93%, which is 19% below median its 10-year median of 11.00. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Return-on-Tangible-Equity is 8.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥42.70 is trading 36.6% below its estimated GF Value™ of ¥67.37.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Possible Value Trap.
Key valuation signals for SHSE:688336:
Return-on-Tangible-Equity: 8.93% (19% below median its 10-year median of 11.00)
GF Value™: ¥67.37 vs. price of ¥42.70 (36.6% below fair value)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
81GF Score
Get the complete analysis for SHSE:688336
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
